Erasca’s RAS-targeted pill shows early tumor shrinkage in pancreatic and lung cancer trials

Erasca reported preliminary data showing its RAS-targeting pill ERAS-0015 shrank tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer patients from studies in the U.S. and China, suggesting potential advantages over a rival drug from Revolution Medicines. While the data are early and the lung results appear more definitive, Erasca says the clinical benefit and tolerability are promising and that all strategic options remain under consideration.